We are facing a new threat to global health. The COVID-19 pandemic made it clear to health-care providers, public health practitioners, policy makers, and communities that pathogens do not respect ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.

Stock markets mostly fell, the dollar slid and and gold hit a record high Wednesday over fears about a trade war between ...

Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for European expansion.

The Shanghai Composite fell 0.7% in afternoon trade. It was the first time the Shanghai market re-opened after the Chinese New Year break. The Hang Seng Index in Hong Kong was down 0.9%. Tokyo's ...

GSK said pretax profit in 2024 fell 43% to GBP3.48 billion from GBP6.06 billion a year prior, though revenue increased 3.5% to GBP31.38 billion from GBP30.33 billion, ahead of the GBP31.05 billion ...

Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance ...